Literature DB >> 21802140

SDF-1/CXCR4 axis in myelodysplastic syndromes: correlation with angiogenesis and apoptosis.

Yizhuo Zhang1, Haifeng Zhao, Dandan Zhao, Lu Sun, Yaqin Zhi, Xiaoxiong Wu, Wenrong Huang, Wanming Da.   

Abstract

To study the role of SDF-1/CXCR4 axis in MDS, the expression of SDF-1 and CXCR4, VEGF, MVD and apoptosis were measured in MDS. The results showed that the expression of SDF-1 of the low-grade MDS is higher than that of the high-grade MDS and the control. The high-grade MDS had a significantly higher CXCR4 expression on CD34+ cell than low-grade MDS and the control. It was suggested that the SDF-1/CXCR4 axis play an important role in MDS. Apoptosis was significantly increased in low-grade MDS, compared with high-grade MDS. The expression of VEGF and MVD were higher in the high-grade MDS than in the low-grade MDS. There are positive correlations between SDF-1 and apoptosis in the low-grade MDS. For the high-grade MDS, there were positive correlations between CXCR4 and VEGF, and between SDF-1 concentration and MVD. The apoptosis is one of the hallmarks for low-grade MDS and the angiogenesis for high-grade MDS. A refined understanding of the roles that SDF-1/CXCR4 axis and its correlation with angiogenesis and apoptosis play in MDS will fuel the development of therapies that can be targeted to the SDF-1/CXCR4 axis.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21802140     DOI: 10.1016/j.leukres.2011.06.017

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  12 in total

Review 1.  The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Authors:  Irene M Ghobrial; Alexandre Detappe; Kenneth C Anderson; David P Steensma
Journal:  Nat Rev Clin Oncol       Date:  2018-01-09       Impact factor: 66.675

2.  Serine protease inhibitor kunitz-type 2 is downregulated in myelodysplastic syndromes and modulates cell-cell adhesion.

Authors:  Fernanda Marconi Roversi; Matheus Rodrigues Lopes; João Agostinho Machado-Neto; Ana Leda F Longhini; Adriana da Silva Santos Duarte; Mariana Ozello Baratti; Bruna Palodetto; Flávia Adolfo Corrocher; Fernando Vieira Pericole; Paula de Melo Campos; Patricia Favaro; Fabiola Traina; Sara Teresinha Olalla Saad
Journal:  Stem Cells Dev       Date:  2014-02-18       Impact factor: 3.272

3.  Expression of CXCR4 is an independent prognostic factor for overall survival and progression-free survival in patients with myelodysplastic syndrome.

Authors:  Yizhuo Zhang; Qing Guo; Haifeng Zhao; Dandan Zhao; Xiaoxiong Wu; Weipeng Zhao; Yafei Wang; Bing Xia; Wanming Da
Journal:  Med Oncol       Date:  2012-12-22       Impact factor: 3.064

4.  CXCL12+ stromal cells as bone marrow niche for CD34+ hematopoietic cells and their association with disease progression in myelodysplastic syndromes.

Authors:  Shiho Abe-Suzuki; Morito Kurata; Shinya Abe; Iichiroh Onishi; Susumu Kirimura; Manami Nashimoto; Toshihiko Murayama; Michihiro Hidaka; Masanobu Kitagawa
Journal:  Lab Invest       Date:  2014-09-08       Impact factor: 5.662

5.  A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes.

Authors:  Eric Huselton; Michael P Rettig; Theresa Fletcher; Julie Ritchey; Leah Gehrs; Kyle McFarland; Stephanie Christ; William C Eades; Kathryn Trinkaus; Rizwan Romee; Shashikant Kulkarni; Armin Ghobadi; Camille Abboud; Amanda F Cashen; Keith Stockerl-Goldstein; Geoffrey L Uy; Ravi Vij; Peter Westervelt; John F DiPersio; Mark A Schroeder
Journal:  Leuk Lymphoma       Date:  2021-01-19

6.  Expression of CXCR4 and CXCL12 and their correlations to the cell proliferation and angiogenesis in mycosis fungoides.

Authors:  Joanna Maj; Alina M Jankowska-Konsur; Agnieszka Hałoń; Zbigniew Woźniak; Ewa Plomer-Niezgoda; Adam Reich
Journal:  Postepy Dermatol Alergol       Date:  2015-12-11       Impact factor: 1.837

7.  Cytokine expression patterns and mesenchymal stem cell karyotypes from the bone marrow microenvironment of patients with myelodysplastic syndromes.

Authors:  H Xiong; X Y Yang; J Han; Q Wang; Z L Zou
Journal:  Braz J Med Biol Res       Date:  2015-01-20       Impact factor: 2.590

8.  [Role of CXCR4/STAT3 in mesenchymal stromal cell-mediated drug resistance of acute leukemia cells].

Authors:  Yungjun Tang; Qing Guo; Yaqin Zhi; Xin Jin; Bing Xia; Shanqi Guo; Chen Tian; Yizhuo Zhang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2016-02

9.  Expression patterns of chemokine receptors on circulating T cells from myelodysplastic syndrome patients.

Authors:  Kristoffer Evebø Sand; Kristin Paulsen Rye; Bård Mannsåker; Oystein Bruserud; Astrid Olsnes Kittang
Journal:  Oncoimmunology       Date:  2013-02-01       Impact factor: 8.110

Review 10.  Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment.

Authors:  Naofumi Mukaida; So-ichiro Sasaki; Tomohisa Baba
Journal:  Mediators Inflamm       Date:  2014-05-22       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.